BioPharma Dive March 10, 2025
Sponsored content By MilliporeSigma
Cell and gene therapy innovators are after “a gene and a dream.”Those are the words of Hugh Murray, Senior Scientist, Upstream Process Development with MilliporeSigma, whose team works with clients to take cell and gene therapy from concept to reality. At the company’s 202,000 square-foot production facility in Carlsbad, California, the CDMO team develops and manufactures processes for viral vector-based therapies. These processes utilize scalable equipment and instrumentation, predictive modeling and automated robotics to maximize throughput while minimizing uncertainty and risk.
“We employ a development strategy designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes efficiently, allowing them to gain an edge on timelines and enter into clinical trials...
Today's Sponsors
Today's Sponsor